Cargando…

Loss of full-length dystrophin expression results in major cell-autonomous abnormalities in proliferating myoblasts

Duchenne muscular dystrophy (DMD) affects myofibers and muscle stem cells, causing progressive muscle degeneration and repair defects. It was unknown whether dystrophic myoblasts—the effector cells of muscle growth and regeneration—are affected. Using transcriptomic, genome-scale metabolic modelling...

Descripción completa

Detalles Bibliográficos
Autores principales: Gosselin, Maxime RF, Mournetas, Virginie, Borczyk, Malgorzata, Verma, Suraj, Occhipinti, Annalisa, Róg, Justyna, Bozycki, Lukasz, Korostynski, Michal, Robson, Samuel C, Angione, Claudio, Pinset, Christian, Gorecki, Dariusz C
Formato: Online Artículo Texto
Lenguaje:English
Publicado: eLife Sciences Publications, Ltd 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514850/
https://www.ncbi.nlm.nih.gov/pubmed/36164827
http://dx.doi.org/10.7554/eLife.75521
_version_ 1784798360095424512
author Gosselin, Maxime RF
Mournetas, Virginie
Borczyk, Malgorzata
Verma, Suraj
Occhipinti, Annalisa
Róg, Justyna
Bozycki, Lukasz
Korostynski, Michal
Robson, Samuel C
Angione, Claudio
Pinset, Christian
Gorecki, Dariusz C
author_facet Gosselin, Maxime RF
Mournetas, Virginie
Borczyk, Malgorzata
Verma, Suraj
Occhipinti, Annalisa
Róg, Justyna
Bozycki, Lukasz
Korostynski, Michal
Robson, Samuel C
Angione, Claudio
Pinset, Christian
Gorecki, Dariusz C
author_sort Gosselin, Maxime RF
collection PubMed
description Duchenne muscular dystrophy (DMD) affects myofibers and muscle stem cells, causing progressive muscle degeneration and repair defects. It was unknown whether dystrophic myoblasts—the effector cells of muscle growth and regeneration—are affected. Using transcriptomic, genome-scale metabolic modelling and functional analyses, we demonstrate, for the first time, convergent abnormalities in primary mouse and human dystrophic myoblasts. In Dmd(mdx) myoblasts lacking full-length dystrophin, the expression of 170 genes was significantly altered. Myod1 and key genes controlled by MyoD (Myog, Mymk, Mymx, epigenetic regulators, ECM interactors, calcium signalling and fibrosis genes) were significantly downregulated. Gene ontology analysis indicated enrichment in genes involved in muscle development and function. Functionally, we found increased myoblast proliferation, reduced chemotaxis and accelerated differentiation, which are all essential for myoregeneration. The defects were caused by the loss of expression of full-length dystrophin, as similar and not exacerbated alterations were observed in dystrophin-null Dmd(mdx-βgeo) myoblasts. Corresponding abnormalities were identified in human DMD primary myoblasts and a dystrophic mouse muscle cell line, confirming the cross-species and cell-autonomous nature of these defects. The genome-scale metabolic analysis in human DMD myoblasts showed alterations in the rate of glycolysis/gluconeogenesis, leukotriene metabolism, and mitochondrial beta-oxidation of various fatty acids. These results reveal the disease continuum: DMD defects in satellite cells, the myoblast dysfunction affecting muscle regeneration, which is insufficient to counteract muscle loss due to myofiber instability. Contrary to the established belief, our data demonstrate that DMD abnormalities occur in myoblasts, making these cells a novel therapeutic target for the treatment of this lethal disease.
format Online
Article
Text
id pubmed-9514850
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher eLife Sciences Publications, Ltd
record_format MEDLINE/PubMed
spelling pubmed-95148502022-09-28 Loss of full-length dystrophin expression results in major cell-autonomous abnormalities in proliferating myoblasts Gosselin, Maxime RF Mournetas, Virginie Borczyk, Malgorzata Verma, Suraj Occhipinti, Annalisa Róg, Justyna Bozycki, Lukasz Korostynski, Michal Robson, Samuel C Angione, Claudio Pinset, Christian Gorecki, Dariusz C eLife Medicine Duchenne muscular dystrophy (DMD) affects myofibers and muscle stem cells, causing progressive muscle degeneration and repair defects. It was unknown whether dystrophic myoblasts—the effector cells of muscle growth and regeneration—are affected. Using transcriptomic, genome-scale metabolic modelling and functional analyses, we demonstrate, for the first time, convergent abnormalities in primary mouse and human dystrophic myoblasts. In Dmd(mdx) myoblasts lacking full-length dystrophin, the expression of 170 genes was significantly altered. Myod1 and key genes controlled by MyoD (Myog, Mymk, Mymx, epigenetic regulators, ECM interactors, calcium signalling and fibrosis genes) were significantly downregulated. Gene ontology analysis indicated enrichment in genes involved in muscle development and function. Functionally, we found increased myoblast proliferation, reduced chemotaxis and accelerated differentiation, which are all essential for myoregeneration. The defects were caused by the loss of expression of full-length dystrophin, as similar and not exacerbated alterations were observed in dystrophin-null Dmd(mdx-βgeo) myoblasts. Corresponding abnormalities were identified in human DMD primary myoblasts and a dystrophic mouse muscle cell line, confirming the cross-species and cell-autonomous nature of these defects. The genome-scale metabolic analysis in human DMD myoblasts showed alterations in the rate of glycolysis/gluconeogenesis, leukotriene metabolism, and mitochondrial beta-oxidation of various fatty acids. These results reveal the disease continuum: DMD defects in satellite cells, the myoblast dysfunction affecting muscle regeneration, which is insufficient to counteract muscle loss due to myofiber instability. Contrary to the established belief, our data demonstrate that DMD abnormalities occur in myoblasts, making these cells a novel therapeutic target for the treatment of this lethal disease. eLife Sciences Publications, Ltd 2022-09-27 /pmc/articles/PMC9514850/ /pubmed/36164827 http://dx.doi.org/10.7554/eLife.75521 Text en © 2022, Gosselin et al https://creativecommons.org/licenses/by/4.0/This article is distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/) , which permits unrestricted use and redistribution provided that the original author and source are credited.
spellingShingle Medicine
Gosselin, Maxime RF
Mournetas, Virginie
Borczyk, Malgorzata
Verma, Suraj
Occhipinti, Annalisa
Róg, Justyna
Bozycki, Lukasz
Korostynski, Michal
Robson, Samuel C
Angione, Claudio
Pinset, Christian
Gorecki, Dariusz C
Loss of full-length dystrophin expression results in major cell-autonomous abnormalities in proliferating myoblasts
title Loss of full-length dystrophin expression results in major cell-autonomous abnormalities in proliferating myoblasts
title_full Loss of full-length dystrophin expression results in major cell-autonomous abnormalities in proliferating myoblasts
title_fullStr Loss of full-length dystrophin expression results in major cell-autonomous abnormalities in proliferating myoblasts
title_full_unstemmed Loss of full-length dystrophin expression results in major cell-autonomous abnormalities in proliferating myoblasts
title_short Loss of full-length dystrophin expression results in major cell-autonomous abnormalities in proliferating myoblasts
title_sort loss of full-length dystrophin expression results in major cell-autonomous abnormalities in proliferating myoblasts
topic Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9514850/
https://www.ncbi.nlm.nih.gov/pubmed/36164827
http://dx.doi.org/10.7554/eLife.75521
work_keys_str_mv AT gosselinmaximerf lossoffulllengthdystrophinexpressionresultsinmajorcellautonomousabnormalitiesinproliferatingmyoblasts
AT mournetasvirginie lossoffulllengthdystrophinexpressionresultsinmajorcellautonomousabnormalitiesinproliferatingmyoblasts
AT borczykmalgorzata lossoffulllengthdystrophinexpressionresultsinmajorcellautonomousabnormalitiesinproliferatingmyoblasts
AT vermasuraj lossoffulllengthdystrophinexpressionresultsinmajorcellautonomousabnormalitiesinproliferatingmyoblasts
AT occhipintiannalisa lossoffulllengthdystrophinexpressionresultsinmajorcellautonomousabnormalitiesinproliferatingmyoblasts
AT rogjustyna lossoffulllengthdystrophinexpressionresultsinmajorcellautonomousabnormalitiesinproliferatingmyoblasts
AT bozyckilukasz lossoffulllengthdystrophinexpressionresultsinmajorcellautonomousabnormalitiesinproliferatingmyoblasts
AT korostynskimichal lossoffulllengthdystrophinexpressionresultsinmajorcellautonomousabnormalitiesinproliferatingmyoblasts
AT robsonsamuelc lossoffulllengthdystrophinexpressionresultsinmajorcellautonomousabnormalitiesinproliferatingmyoblasts
AT angioneclaudio lossoffulllengthdystrophinexpressionresultsinmajorcellautonomousabnormalitiesinproliferatingmyoblasts
AT pinsetchristian lossoffulllengthdystrophinexpressionresultsinmajorcellautonomousabnormalitiesinproliferatingmyoblasts
AT goreckidariuszc lossoffulllengthdystrophinexpressionresultsinmajorcellautonomousabnormalitiesinproliferatingmyoblasts